Gross Margin for Q4 FY24 is 57.8% compared to 54.6% in Q4 FY23 and 12M FY24 is 57.3% compared to 54.8% in 12M FY23
EBITDA Margin for Q4 FY24 is 34.5% compared to 33.8% in Q4 FY23 and 12M FY24 is higher at 35.1% compared to 32.6% in 12M FY23, aided by new product launches across existing and new markets in the current year
Basic EPS increased by 21.3% to ₹60.19 in 12M FY24 compared to ₹49.62 in 12M FY23
Cash Flow from Operations in 12M FY24 is ₹318 Crores as compared to ₹271 Crores in 12M FY23
Free Cash Flow is ₹172 Crores (after Capex investment of ₹146 Crores) in 12M FY24 as compared
to ₹78 Crores (after capex investment of ₹194 Crores) in 12M FY23
Geographical revenues: Latin America and Rest of World 82%, US 18%
Caplin Steriles Ltd (“CSL”) revenue crosses ₹100Cr for the first time in Q4 FY24. 12M FY24
Operating Revenue of ₹313.36 Crores, with 51% Y-o-Y growth
CSL’s revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit
Share, with the split for 12M FY24 in the range of 75% and 25% respectively.
As of 31st Mar 2024, Inventories (including in-transit inventory) are at ₹363 Crores and Free Cash
Reserves are at ₹910.50 Crores. The total Liquid Assets of the Company (Inventory + Receivables +Free Cash Reserves) are at ₹1,816 Crores. Receivable days are at 114 days.
Overall inline number and book value per share Rs 309/-
Subscribe To Our Free Newsletter |